Back to Search Start Over

Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?

Authors :
Erika, Esteve-Pitarch
Víctor Daniel, Gumucio-Sanguino
Sara, Cobo-Sacristán
Evelyn, Shaw
Kristel, Maisterra-Santos
Joan, Sabater-Riera
Xosé L, Pérez-Fernandez
Raül, Rigo-Bonnin
Fe, Tubau-Quintano
Jordi, Carratalà
Helena, Colom-Codina
Ariadna, Padullés-Zamora
Source :
European journal of drug metabolism and pharmacokinetics. 46(4)
Publication Year :
2021

Abstract

Morbidity and mortality from serious infections are common in intensive care units (ICUs). The appropriateness of the antibiotic treatment is essential to combat sepsis. We aimed to evaluate pharmacokinetic/pharmacodynamic target attainment of meropenem and piperacillin/tazobactam administered at standard total daily dose as continuous infusion in critically ill patients without renal dysfunction and to identify risk factors of non-pharmacokinetic/pharmacodynamic target attainment.We included 118 patients (149 concentrations), 47% had microorganism isolation. Minimum inhibitory concentration (MIC) [median (interquartile range, IQR) values in isolated pathogens were: meropenem: 0.05 (0.02-0.12) mg/l; piperacillin: 3 (1-4) mg/l]. Pharmacokinetic/pharmacodynamic target attainments (100%fCStandard total daily dose of meropenem allowed achieving pharmacokinetic/pharmacodynamic target attainments in ICU patients without renal dysfunction. Higher doses of piperacillin/tazobactam would be needed to cover microorganisms with MIC8 mg/l. CrCL was the most powerful factor predictive of fC

Details

ISSN :
21070180
Volume :
46
Issue :
4
Database :
OpenAIRE
Journal :
European journal of drug metabolism and pharmacokinetics
Accession number :
edsair.pmid..........2b63ba59d601568648b769ef4170d9cc